Evidence map›Paper›PMID 37262055›Full record

ArticlePLoS neglected tropical diseases2023

Low responsiveness of peripheral lymphocytes in extraparenchymal neurocysticercosis.

Matthew L Romo, Rocio Osorio, Andrea Toledo, Roger Carrillo-Mezo, Ricardo Valdez, Marta C Romano, Edda Sciutto, Gladis Fragoso, Agnès Fleury

Open access · goldAbstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Repair capacity ofFuture microbiology · 2025
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Matthew L RomoDepartment of Epidemiology & Biostatistics, CUNY Graduate School of Public Health and Health Policy, City University of New York, New York, United States of America.
Rocio OsorioUnidad de Neuro inflamación, Departamento de Medicina Genómica y Toxicología ambiental, Instituto de Investigación Biomédicas, Universidad Nacional Autónoma de México (UNAM) / Instituto Nacional de Neurología y Neurocirugía, Ciudad de México, México.
Andrea ToledoUnidad de Neuro inflamación, Departamento de Medicina Genómica y Toxicología ambiental, Instituto de Investigación Biomédicas, Universidad Nacional Autónoma de México (UNAM) / Instituto Nacional de Neurología y Neurocirugía, Ciudad de México, México.
Roger Carrillo-MezoNeuroradiology Department, Instituto Nacional de Neurología y Neurocirugía, Ciudad de México, México.
Ricardo ValdezCINVESTAV, Departamento de Fisiología, Biofísica y Neurociencias, México.
Marta C RomanoCINVESTAV, Departamento de Fisiología, Biofísica y Neurociencias, México.
Edda SciuttoDepartamento de Inmunología, Instituto de Investigación Biomédicas, Universidad Nacional Autónoma de México (UNAM), Ciudad de México, México.
Gladis FragosoDepartamento de Inmunología, Instituto de Investigación Biomédicas, Universidad Nacional Autónoma de México (UNAM), Ciudad de México, México.
Agnès FleuryUnidad de Neuro inflamación, Departamento de Medicina Genómica y Toxicología ambiental, Instituto de Investigación Biomédicas, Universidad Nacional Autónoma de México (UNAM) / Instituto Nacional de Neurología y Neurocirugía, Ciudad de México, México.ORCID 0000-0002-8930-2202
Instituto Nacional de Neurología y Neurocirugía · MXCentro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional · MXUniversidad Nacional Autónoma de México · MXCity University of New York · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe morbidity and mortality of extraparenchymal neurocysticercosis (EP-NC) remain high and effectiveness of current medical treatment is suboptimal. Various factors have been implicated in the severity of EP-NC and in the poor response to treatment, but the possible role of host immune and endocrine systems has not yet been examined thoroughly. METHODOLOGY/PRINCIPAL

findings42 participants with EP-NC before receiving standard treatment and 25 healthy controls were included in the study. Treatment response was assessed by comparing pre/post treatment parasite volumes from 3D MRI. Prior to treatment among participants with EP-NC, specific stimulation induced an increased specific proliferative response accompanied by a significant increase in IL-4, NK, NKT, Bregs and Tregs cells, whereas in healthy controls, specific stimulation induced a significant increase in IL-1β, IL-5, CCL5, IL-6, TNF-α, NK and Bregs cells. Significant differences between participants with EP-NC and healthy controls in the specific inflammatory response were observed. Participants with EP-NC prior to treatment had significantly weaker responses of proinflammatory cytokines (IL-6, TNF-α) and NK cells, and stronger IL-4 response. Anthelmintic treatment did not promote significant peripheral immunological changes at any time, although inflammation was sustained in the cerebrospinal fluid. Serum estradiol concentration significantly decreased after anthelmintic treatment among males, and cortisol correlated negatively with IL-6 and positively with IFN-γ levels. No pre-treatment immunologic or endocrinologic parameters were significantly associated with response to treatment. CONCLUSION/SIGNIFICANCE: Prior to anthelmintic treatment, EP-NC was characterized by low lymphocyte reactivity accompanied by a regulatory response, which may be involved in the lack of peripheral immunological changes during and after treatment, although a central inflammatory response was present. This weak specific peripheral response could favor the chronicity of the infection and the poor response to treatment. Our findings highlight the need for new anti-inflammatory treatment focused on the central nervous system with less systemic immunosuppressive effects.

Indexed as

NeurocysticercosisCytokinesHumansInterleukin-4Interleukin-6Killer Cells, NaturalMaleTumor Necrosis Factor-alphaCytokinesInterleukin-4Interleukin-6Tumor Necrosis Factor-alpha

Identifiers

PMID37262055
PMCPMC10263342
OpenAlexW4379056559

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.